Drug Hepatotoxicity, An Issue of Clinics in Liver Disease
- 1st Edition, Volume 21-1 - November 16, 2016
- Latest edition
- Author: Vinod K. Rustgi
- Language: English
Dr. Rustgi has assembled the leading experts in the management of Heptatitis B to present the current treatment and clinical course for diagnosis and management of the disease.… Read more
Purchase options
Description
Description
Dr. Rustgi has assembled the leading experts in the management of Heptatitis B to present the current treatment and clinical course for diagnosis and management of the disease. Articles are devoted to: Drug metabolism in the liver; Mechanism of Liver Damage including the RUCAM scale; Drug-induced acute liver failure; Epidemiology and genetic risk factors; Adverse drug reactions: type A (intrinsic or pharmacological) or type B (idiosyncratic); Pathology of injury including phenotypes; The clinical course of drug-induced liver disease; Environmental factors of drug hepatotoxicity; Newer agents in drug hepatotoxicity; Drug hepatotoxicity: herbal products; Drug hepatotoxicity: models including “human on a chip” and zebrafish; Acute and chronic liver failure from drugs: impact on the kidney; and Management of acute hepatotoxicity including medical agents and liver support systems. Readers will come away with the cutting edge science behind the latest innovations in the treatment of Hepatitis B.
Product details
Product details
- Edition: 1
- Latest edition
- Volume: 21-1
- Published: November 16, 2016
- Language: English
About the author
About the author
VR
Vinod K. Rustgi
Dr. Vinod Rustgi is a Professor in Epidemiology in the School of Public Health and a Professor in Pathology and Lab Medicine. He previously served as Program Director for the Gastroenterology Fellowship until the 2022/2023 academic year and currently serves as Associate Program Director. He has extensive experience in hepatology spanning over 30 years and previously held the position of Medical Director of Liver Transplantation at the University of Pittsburgh’s Starzl Transplant Institute. His research and clinical interests include outcomes research in nonalcoholic steatohepatitis (NASH), other liver diseases, and cost-effectiveness modeling. He has contributed to antiviral research associated with hepatitis C cure efforts and has served on the Governing Board of the American Association for the Study of Liver Diseases (AASLD).
Affiliations and expertise
Distinguished Professor, Associate Program Director, Clinical Director of Hepatology, and Director, Center for Liver Diseases, Robert Wood Johnson Medical School (RWJMS), Rutgers Health, New Brunswick, NJ, USA